Pierfrancesco Franco1, Francesca Arcadipane2, Riccardo Ragona2, Massimiliano Mistrangelo3, Paola Cassoni4, Nadia Rondi5, Mario Morino3, Patrizia Racca6, Umberto Ricardi2. 1. Department of Oncology-Radiation Oncology, University of Turin, Turin, Italy pierfrancesco.franco@unito.it. 2. Department of Oncology-Radiation Oncology, University of Turin, Turin, Italy. 3. Department of Surgical Sciences, University of Turin, Turin, Italy. 4. Department of Medical Sciences, University of Turin, Turin, Italy. 5. Department of Medical Imaging and Radiotherapy, Radiation Oncology, AOU Città della Salute e della Scienza, Turin, Italy. 6. Oncological Centre for Gastrointestinal Neoplasm, Medical Oncology 1, AOU Città della Salute e della Scienza, Turin, Italy.
Abstract
AIM: To report on clinical outcomes of a consecutive series of locally advanced (T3-T4N0-N3) anal cancer patients treated with intensity-modulated radiotherapy (IMRT) and a simultaneous integrated boost (SIB) approach similarly to the RTOG 05-29 trial. PATIENTS AND METHODS: A cohort of 45 patients underwent SIB-IMRT employing a schedule consisting of 54 Gy/30 fractions to the macroscopic anal planning target volume (PTV), while clinical nodes were prescribed 50.4 Gy/30 fractions if sized ≤3 cm or 54 Gy/30 fractions if >3 cm. Elective nodal PTV was prescribed 45 Gy/30 fractions. Chemotherapy was administered concurrently following the Nigro regimen. Primary end-point was colostomy-free survival (CFS). Secondary end-points were locoregional control (LRC), disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS). RESULTS: Median follow-up was 39.7 months. The actuarial 3-year CFS was 63.4 % (95% confidence interval (CI=44.8-77.1%). Actuarial 3-year OS and CSS were 67.7% (95%CI=48.7-80.9%) and 72.9% (95%CI=53.8-85.1%), while DFS was 55.8% (95%CI=37.5.4-70.7%). Actuarial 3-year LRC was 74.1% (95%CI=56.7-85.4%). On multivariate analysis, male sex (hazard ratio (HR)=10.9; p=0.004; 95%CI=2.2-55.5%) had a significant impact on CFS, while higher clinical stage (Stage IIIB vs. others) had borderline significance (HR=2.7; p=0.062; 95%CI=1.8-5.9%). A shorter package time (HR=0.94; p=0.007; 95%CI=0.91-0.98%) predicted for higher CFS. Maximum detected events included: skin (G3): 13%; gastrointestinal (GI) (G3): 13%; genitourinary (GU) (G2): 38%; genitalia (G2): 45%; anemia (G2): 4%; leukopenia (G3): 24%, (G4):7%; neutropenia (G3): 16%; (G4): 11%; thrombocytopenia (G3): 9%, (G4): 2%. CONCLUSION: Our clinical results support the use of SIB-IMRT in the combined modality treatment of locally advanced anal cancer patients. Copyright
AIM: To report on clinical outcomes of a consecutive series of locally advanced (T3-T4N0-N3) anal cancerpatients treated with intensity-modulated radiotherapy (IMRT) and a simultaneous integrated boost (SIB) approach similarly to the RTOG 05-29 trial. PATIENTS AND METHODS: A cohort of 45 patients underwent SIB-IMRT employing a schedule consisting of 54 Gy/30 fractions to the macroscopic anal planning target volume (PTV), while clinical nodes were prescribed 50.4 Gy/30 fractions if sized ≤3 cm or 54 Gy/30 fractions if >3 cm. Elective nodal PTV was prescribed 45 Gy/30 fractions. Chemotherapy was administered concurrently following the Nigro regimen. Primary end-point was colostomy-free survival (CFS). Secondary end-points were locoregional control (LRC), disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS). RESULTS: Median follow-up was 39.7 months. The actuarial 3-year CFS was 63.4 % (95% confidence interval (CI=44.8-77.1%). Actuarial 3-year OS and CSS were 67.7% (95%CI=48.7-80.9%) and 72.9% (95%CI=53.8-85.1%), while DFS was 55.8% (95%CI=37.5.4-70.7%). Actuarial 3-year LRC was 74.1% (95%CI=56.7-85.4%). On multivariate analysis, male sex (hazard ratio (HR)=10.9; p=0.004; 95%CI=2.2-55.5%) had a significant impact on CFS, while higher clinical stage (Stage IIIB vs. others) had borderline significance (HR=2.7; p=0.062; 95%CI=1.8-5.9%). A shorter package time (HR=0.94; p=0.007; 95%CI=0.91-0.98%) predicted for higher CFS. Maximum detected events included: skin (G3): 13%; gastrointestinal (GI) (G3): 13%; genitourinary (GU) (G2): 38%; genitalia (G2): 45%; anemia (G2): 4%; leukopenia (G3): 24%, (G4):7%; neutropenia (G3): 16%; (G4): 11%; thrombocytopenia (G3): 9%, (G4): 2%. CONCLUSION: Our clinical results support the use of SIB-IMRT in the combined modality treatment of locally advanced anal cancerpatients. Copyright
Authors: V Dell'Acqua; J Kobiela; F Kraja; M C Leonardi; A Surgo; M A Zerella; S Arculeo; C Fodor; R Ricotti; M G Zampino; S Ravenda; G Spinoglio; R Biffi; A Bazani; R Luraschi; S Vigorito; P Spychalski; R Orecchia; R Glynne-Jones; B A Jereczek-Fossa Journal: Med Oncol Date: 2018-03-28 Impact factor: 3.064
Authors: Devarati Mitra; Theodore S Hong; Nora Horick; Brent Rose; Lorraine N Drapek; Lawrence S Blaszkowsky; Jill N Allen; Eunice L Kwak; Janet E Murphy; Jeffrey W Clark; David P Ryan; James C Cusack; Liliana G Bordeianou; David L Berger; Jennifer Y Wo Journal: Adv Radiat Oncol Date: 2017-02-06
Authors: Wang Lan; Liu Lihong; Han Chun; Liu Shutang; Wang Qi; Xu Liang; Li Xiaoning; Liu Likun Journal: Strahlenther Onkol Date: 2022-01-14 Impact factor: 4.033